A phase II trial to study rare tumors

IRB17-090
Cancer, Cancer - Brain, Cancer - Breast, Cancer - Colon, Cancer - Esophogus, Cancer-Gynecologic, Cancer - Kidney, Cancer - Leukemia, Cancer - Lung, Cancer - Lymphoma, Cancer - Melanoma, Cancer - Multiple Myeloma, Cancer - Pancreatic, Cancer - Prostate
John McCann, MD
D'Amour Center for Cancer Care
3350 Main Street
Springfield, MA 01199

Baystate Franklin Medical Center
164 High Street
Greenfield, MA 01301
The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin. The combination treatment of ipilimumab and nivolumab could shrink your cancer but it could also cause side effects.
Patients must have histologically confirmed rare cancer and/or cancer of unknown primary, that did not have a match to a molecularly-guided therapy on EAY131 “NCI-MATCH” protocol or who progressed on molecularly-matched therapy and have no further molecularly-matched treatment recommendations per EAY131, “NCI-MATCH”.
Betsy Lopez
(413)794-4154